Secondary Logo

Therapeutic and Recreational Marijuana

Safe Practice Within the Web of Politics, Science, Law, and Nursing

doi: 10.1097/NUR.0000000000000450
DEPARTMENTS: CE Test
Free
CE

Instructions:

  • Read the article. The test for this CE activity can only be taken online at http://www.nursingcenter.com/ce/CNS. Tests can no longer be mailed or faxed.
  • You will need to create (its free!) and login to your personal CE Planner account before taking online tests. Your planner will keep track of all your Lippincott Professional Development online CE activities for you.
  • There is only one correct answer for each question. A passing score for this test is 12 correct answers. If you pass, you can print your certificate of earned contact hours and access the answer key. If you fail, you have the option of taking the test again at no additional cost.
  • For questions, contact Lippincott Professional Development: 1-800-787-8985.

Registration Deadline: June 4, 2021

Disclosure Statement:

The author and planners have disclosed no potential conflicts of interest, financial or otherwise.

Provider Accreditation:

Lippincott Professional Development will award 1.0 contact hour for this continuing nursing education activity. This activity has been assigned 0.5 pharmacology credits.

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.0 contact hour. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia and Florida, CE Broker #50-1223.

Payment:

  • The registration fee for this test is $12.95.
Back to Top | Article Outline

CE TEST QUESTIONS

PURPOSE: To provide information on therapeutic and recreational marijuana.

LEARNING OBJECTIVES/OUTCOMES: After completing this continuing education activity, you should be able to:

1. Recognize the desired effects and potential adverse effects of marijuana.

2. Analyze selected legislation related to marijuana as well as current uses for the drug.

  1. Delta-9-tetrahydrocannabinol (THC) has a half-life of
    1. 1 to 3 hours.
    2. 12 to 16 hours.
    3. 1 to 3 days.
  2. As opposed to the effects of THC, the effects of cannabidiol (CBD) are
    1. anxiolytic.
    2. euphoric.
    3. anxiogenic.
  3. What legislation defined cannabis as a Schedule I substance in the United States?
    1. the Geneva Trafficking Conventions of 1936
    2. the Federal Marijuana Tax Act of 1937
    3. the Federal Controlled Substance Act of 1970
  4. Federal law categorizes marijuana as a drug
    1. with low potential for abuse.
    2. without accepted medical use.
    3. with minimal proven benefits.
  5. As noted in the article, there is insufficient evidence to support or refute that cannabis or cannabinoids are an effective treatment for any of the following except
    1. chronic pain in adults.
    2. Parkinson’s disease.
    3. schizophrenia in adults.
  6. Which agent and purpose have conclusive/substantive evidence supporting its use?
    1. THC capsules for improvement in symptoms of Tourette syndrome
    2. nabilone (Cesamet) for improvement in symptoms of posttraumatic stress disorder
    3. oral cannabinoids for chemotherapy-induced nausea and vomiting
  7. There is moderate evidence for the use of
    1. cannabis for improvement in symptoms in amyotrophic lateral sclerosis.
    2. cannabis or cannabinoids for improvement in fibromyalgia symptoms.
    3. cannabis and oral cannabinoids for decreased weight loss in HIV/AIDS.
  8. The evidence supporting the therapeutic use of oral cannabinoids for improvement in clinician-measured multiple sclerosis spasticity is
    1. limited.
    2. moderate.
    3. conclusive/substantive.
  9. The author notes that long-term smoking of cannabis is associated with
    1. early onset of Alzheimer’s disease.
    2. more frequent episodes of chronic bronchitis.
    3. the development of non–small cell lung cancer.
  10. Which state enacted the first state law legalizing the use of cannabis as an option for analgesia and antiemesis for patients with AIDS?
    1. California
    2. Oregon
    3. Washington
  11. The efficacy of marijuana for treating cancer pain is
    1. weak.
    2. moderate.
    3. conclusive.
  12. Which statement is true regarding CBD or cannabis?
    1. Current plant design is focused on maximizing CBD content alone.
    2. CBD has analgesia and anti-inflammatory activity.
    3. Evidence suggests that cannabis should be considered the best choice for pain management.
  13. Compared to peers who do not use cannabis, use of cannabis by adolescents is associated with all of the following except
    1. alterations in grey matter volume.
    2. lower educational attainment.
    3. increased alertness.
  14. Women who are pregnant or contemplating pregnancy should be encouraged to stop marijuana use based on concerns for impairment in
    1. bone development.
    2. lung development.
    3. neurodevelopment.
  15. Which statement is true regarding cannabis use?
    1. It is “natural” and therefore safe.
    2. Users experience rebound hyperalgesia with forced abrupt cessation.
    3. Continued use has not been shown to cause dependence or addiction.
  16. The author suggests that the most important information shared between the clinical nurse specialist and the patient may relate to using cannabis and
    1. climbing a ladder or other high structure.
    2. making important legal decisions.
    3. operating a motor vehicle.
  17. As noted in the article, a consequence of legalization of marijuana in Colorado and Washington was an increase in emergency room visits, particularly for
    1. children exposed to marijuana due to poor supervision and/or unsafe storage of cannabis.
    2. adolescents who used other illicit drugs and/or alcohol.
    3. adults who used marijuana “laced” with other drugs such as phencyclidine or cocaine.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved